AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Redwood City, California.
Company Growth (employees)
Redwood City, US
Size (employees)
39 (est)+9%
AcelRx Pharmaceuticals is headquartered in Redwood City, US

AcelRx Pharmaceuticals Office Locations

AcelRx Pharmaceuticals has an office in Redwood City
Redwood City, US (HQ)
351 Galveston Dr

AcelRx Pharmaceuticals Metrics

AcelRx Pharmaceuticals Financial Metrics

Revenue (2016)

$17.4 m

Revenue growth (2015-16), %


Gross profit

$5 m

Gross profit margin (2016), %


Net income (2016)

($43.2 m)

Market capitalization (21-Mar-2017)

$138.3 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$80.3 m
AcelRx Pharmaceuticals's current market capitalization is $138.3 m.
AcelRx Pharmaceuticals's revenue was reported to be $17.4 m in FY, 2016 which is a 9.9% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$29.5 m$5.2 m$19.3 m$17.4 m

Revenue growth, %


Cost of goods sold

$1.8 m$12.3 m

Gross profit

$17.5 m$5 m

Gross profit Margin, %


Operating expense total

$36.2 m$42.9 m$39.2 m$49.3 m


($21.9 m)($30.7 m)($20 m)($32 m)

EBIT margin, %


Interest expense

$3 m$2.8 m

Pre tax profit

($23.6 m)($43.2 m)

Income tax expense

($760 k)

Net Income

($23.4 m)($33.4 m)($24.4 m)($43.2 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$88.4 m$60 m$107.9 m$80.3 m

Accounts Receivable

$3.3 m$5.8 m


$897 k$948 k$466 k$2.2 m

Current Assets

$104.6 m$76.3 m$118.9 m$89.1 m


$5.2 m$9.8 m$8.6 m$10.7 m

Total Assets

$110 m$86.4 m$127.8 m$100 m

Accounts Payable

$2.3 m$2.4 m$1.6 m$1.6 m

Current Liabilities

$6.9 m$13.7 m$12.8 m$10.2 m

Additional Paid-in Capital

$218.6 m$225.4 m$236.3 m$241 m

Retained Earnings

($145.5 m)($178.8 m)($203.2 m)($246.4 m)

Total Equity

$73.2 m$33.1 m

Financial Leverage

1.5 x3.9 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($23.4 m)($33.4 m)($24.4 m)($43.2 m)

Depreciation and Amortization

$593 k$866 k$2 m$2.1 m

Accounts Receivable

($3.3 m)($2.5 m)


($466 k)($1.7 m)

Accounts Payable

$106 k$90 k($786 k)($437 k)

Cash From Operating Activities

($487 k)($34.5 m)($20 m)($29.4 m)

Purchases of PP&E

($3.3 m)($5.5 m)($1.5 m)($3.7 m)

Cash From Investing Activities

($6.9 m)($5.8 m)$8.2 m$1.8 m

Interest Paid

$1.1 m$1.8 m$2.1 m$1.9 m

Income Taxes Paid

$782 k

AcelRx Pharmaceuticals Market Value History

AcelRx Pharmaceuticals Online Presence

AcelRx Pharmaceuticals News

AcelRx Pharmaceuticals Company Life

You may also be interested in